Details

Autor(en) / Beteiligte

• Kuzuya, Teiji
• Kawabe, Naoto
• Hashimoto, Senju
• Funasaka, Kohei
• Nagasaka, Mitsuo
• Nakagawa, Yoshihito
• Miyahara, Ryoji
• Shibata, Tomoyuki
• Takahara, Takeshi
• Kato, Yutaro
• Sugioka, Atsushi
• Hirooka, Yoshiki

Titel

Clinical Outcomes of Ramucirumab as Post-treatment Following Atezolizumab/Bevacizumab Combination Therapy in Advanced Hepatocellular Carcinoma

Ist Teil von

• Anticancer research, 2022-04, Vol.42 (4), p.1905-1910

Ort / Verlag

Greece: International Institute of Anticancer Research

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• The present study evaluated the efficacy and safety of ramucirumab (RAM) in clinical practice as post-treatment, following atezolizumab plus bevacizumab (Atz/Bev) for advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein (AFP) levels of ≥400 ng/ml. Of the 77 patients treated with Atz/Bev at our institution, 13 patients for whom RAM was introduced as post-treatment following Atz/Bev were enrolled in this retrospective study. There were 9 patients (69.2%) with Child-Pugh A and 11 patients (84.6%) for whom RAM was initiated as 3 - or later-line therapy. The median AFP level was 2259 ng/ml. The objective response rate by Response Evaluation Criteria in Solid Tumours at 6 weeks was 15.4%, and the disease control rate was 69.2%. The median time to progression was 3.0 months; AFP level decreased at 2 weeks in 11 patients (84.6%) and at 6 weeks in seven patients (53.8%). The most common adverse events (AEs) within 6 weeks were ascites, peripheral oedema, and proteinuria, while grade 3 AEs occurred in six patients (46.2%). Albumin-bilirubin scores at both 4 and 6 weeks were significantly worse than those at baseline. In HCC patients with AFP levels of ≥400 ng/mL, RAM after Atz/Bev is expected to be an effective treatment option. Careful attention should be paid to the development of AEs and deterioration of liver function, especially when RAM is used as 3 - or later-line therapy. Additional studies are needed to confirm the efficacy and safety of RAM as 2 -line treatment after Atz/Bev in Child-Pugh A patients.